Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-789: Pembrolizumab + platinum/pemetrexed in TKI-resistant EGFR-mutated metastatic non-squamous NSCLC
jRCT2080223961Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + pemetrexed + platinum with Placebo + pemetrexed + platinum (2 arms). Primary endpoints: Overall survival and Progression-free survival (BICR). Started Jul 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223961.